On October 17, 2016 Eli Lilly and Company (NYSE: LLY) reported it will contribute cancer research data to the National Cancer Institute’s Blood Profiling Atlas, an open access liquid biopsy database being created in response to Vice President Joe Biden’s call to action and in alignment with the goals of the Cancer Moonshot initiative (Press release, Eli Lilly, OCT 17, 2016, View Source [SID1234515873]). The database is an effort to reduce the development time of effective and safe blood profiling diagnostic technologies. Schedule your 30 min Free 1stOncology Demo! "We are honored to be a part of this unique partnership," said Andrew Schade, M.D., Ph.D., a distinguished medical fellow in Lilly’s clinical diagnostics laboratory. "Liquid biopsies are going to be critical in the future to both identify specific patients for targeted therapies and to follow their treatment to better determine response to therapy. We hope knowledge gained from our research efforts in this area will help to accelerate the development of safe and effective blood profiling diagnostic technologies that help people with cancer."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In support of this overarching mission, Lilly is studying approaches for the profiling of exosomes for mRNA and non-coding RNA expression and will share sample preparation methods, next-generation quantitative PCR-based methods, and next generation sequencing-based methods along with data related to disease characterization through gene expression analysis.
"Our scientists are dedicated to discovering and developing new cancer treatments to help people living with this disease," said Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories. "In addition to our own research, external partnerships are paramount, and we look forward to collaborating with other experts as part of the Cancer Moonshot initiative."
The Blood Profiling Atlas is part of the Cancer Moonshot initiative, which was established to improve the way research is conducted and expedite the delivery of medicines to patients. Allowing approved researchers access to raw unprocessed datasets in a scalable and reproducible manner, the open database will feature the following data: raw data sets from circulating tumor cells, circulating tumor DNA, and exosome assays, as well as relevant clinical data, sample preparation, and handling protocols from 12 different studies. The Blood Profiling Atlas pilot will be curated by a partnership between the University of Chicago and Seven Bridges, a biomedical data analysis company. For more information about the Blood Profiling Atlas, please click here.